Acorda Therapeutics Inc. (ACOR)
Acorda Therapeutics Statistics
Share Statistics
Acorda Therapeutics has 1.24M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 1.24M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.22M |
| Failed to Deliver (FTD) Shares | 5K |
| FTD / Avg. Volume | 3.98% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.07 and the forward PE ratio is null. Acorda Therapeutics's PEG ratio is 0.
| PE Ratio | -0.07 |
| Forward PE | n/a |
| PS Ratio | 0.16 |
| Forward PS | n/a |
| PB Ratio | -0.12 |
| P/FCF Ratio | -1.32 |
| PEG Ratio | 0 |
Enterprise Valuation
Acorda Therapeutics has an Enterprise Value (EV) of 179.28M.
| EV / Sales | 1.52 |
| EV / EBITDA | 21.34 |
| EV / EBIT | -12.82 |
| EV / FCF | -12.58 |
Financial Position
The company has a current ratio of 0.33, with a Debt / Equity ratio of -1.21.
| Current Ratio | 0.33 |
| Quick Ratio | 0.26 |
| Debt / Equity | -1.21 |
| Debt / EBITDA | 22.72 |
| Debt / FCF | -13.4 |
| Interest Coverage | -0.74 |
Financial Efficiency
Return on Equity is 160.08% and Return on Invested Capital is -60.32%.
| Return on Equity | 160.08% |
| Return on Assets | -214.75% |
| Return on Invested Capital | -60.32% |
| Revenue Per Employee | $1.15M |
| Profits Per Employee | $-2.48M |
| Employee Count | 102 |
| Asset Turnover | 1 |
| Inventory Turnover | 2.85 |
Taxes
| Income Tax | -43.17M |
| Effective Tax Rate | 14.58% |
Stock Price Statistics
The stock price has increased by 20% in the last 52 weeks. The beta is 1.46, so Acorda Therapeutics's price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | 20% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 2.07 |
| Relative Strength Index (RSI) | 45.91 |
| Average Volume (20 Days) | 125.68K |
Income Statement
In the last 12 months, Acorda Therapeutics had revenue of 117.63M and earned -252.85M in profits. Earnings per share was -203.59.
| Revenue | 117.63M |
| Gross Profit | 71.59M |
| Operating Income | -23.26M |
| Net Income | -252.85M |
| EBITDA | 8.4M |
| EBIT | -233.49M |
| Earnings Per Share (EPS) | -203.59 |
Balance Sheet
The company has 30.36M in cash and 190.9M in debt, giving a net cash position of -160.54M.
| Cash & Cash Equivalents | 30.36M |
| Total Debt | 190.9M |
| Net Cash | -160.54M |
| Retained Earnings | -1.19B |
| Total Assets | 81.58M |
| Working Capital | -175.48M |
Cash Flow
In the last 12 months, operating cash flow was -13.98M and capital expenditures -264K, giving a free cash flow of -14.25M.
| Operating Cash Flow | -13.98M |
| Capital Expenditures | -264K |
| Free Cash Flow | -14.25M |
| FCF Per Share | -11.47 |
Margins
Gross margin is 60.86%, with operating and profit margins of -19.78% and -214.95%.
| Gross Margin | 60.86% |
| Operating Margin | -19.78% |
| Pretax Margin | -251.65% |
| Profit Margin | -214.95% |
| EBITDA Margin | 7.14% |
| EBIT Margin | -19.78% |
| FCF Margin | -12.11% |
Dividends & Yields
ACOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1349.15% |
| FCF Yield | -76.02% |
Analyst Forecast
Currently there are no analyst rating for ACOR.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 5, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Jun 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -23 |
| Piotroski F-Score | 3 |